Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CDK14 | O94921 | 4/20 | 0.38 |
| ▸ | CCNY | Q8ND76 | 4/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281485 | 0.87 | GRM5 (0.43) | GRM5P2RX7IRAK4CDK14CCNY | |
| SCHEMBL4279992 | 0.86 | GRM5 (0.46) | GRM5P2RX7IRAK4CDK14CCNY | |
| SCHEMBL4284286 | 0.85 | GRM5 (0.42) | GRM5P2RX7IRAK4CDK14CCNY | |
| SCHEMBL4283563 | 0.84 | GRM5 (0.47) | GRM5P2RX7IRAK4CD274MEN1 | |
| SCHEMBL4288450 | 0.84 | GRM5 (0.44) | GRM5P2RX7IRAK4MEN1KMT2A | |
| SCHEMBL4279957 | 0.83 | HDAC3 (0.44) | KMT2AKDM4EGAA | |
| SCHEMBL4287245 | 0.83 | GRM5 (0.45) | GRM5P2RX7MEN1KMT2AMAPK8 | |
| SCHEMBL4288777 | 0.83 | GRM5 (0.45) | GRM5P2RX7MEN1KMT2AMAPK8 | |
| SCHEMBL4285811 | 0.81 | GRM5 (0.43) | GRM5P2RX7IRAK4CDK14CCNY | |
| SCHEMBL4285745 | 0.81 | GRM5 (0.43) | GRM5P2RX7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | GRM5 3842/4885P2RX7 1137/4885IRAK4 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.